LPL Financial
CNST

LPL Financial’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

LPL Financial’s Portfolio CNST Stock Details CNST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-12,464
Closed -$392K – 3536
2020
Q1 		$392K Buy
+12,464
New +$433K ﹤0.01% 2274

Other funds holding CNST

PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VMV
Venrock Management V Palo Alto, California $719M AUM
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

LPL Financial's CNST Position: Q2 2020 in Review

LPL Financial sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q2 2020, closing a stake of 12,464 shares — an estimated $392K sold.

LPL Financial first reported a position in CNST in Q1 2020 and held it in 1 quarter. The position peaked at $392K in Q1 2020. 132 funds tracked by Wall St. Rank hold CNST as of Q2 2020.

  • LPL Financial reported no remaining Constellation Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
  • LPL Financial sold 12,464 Constellation Pharmaceuticals, Inc. shares in Q2 2020, an estimated $392K.
  • LPL Financial first reported a position in Constellation Pharmaceuticals, Inc. in Q1 2020 and held it in 1 quarter.
  • LPL Financial's Constellation Pharmaceuticals, Inc. position peaked at $392K in Q1 2020.
  • 132 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q2 2020.

Based on LPL Financial's 13F filing for Q2 2020, filed 13 Aug 2020.